TransCode Therapeutics (NASDAQ:RNAZ) Shares Down 5.6% – Should You Sell?

TransCode Therapeutics Inc. (NASDAQ:RNAZ)’s share price fell 5.6% on Wednesday . The stock traded as low as $5.01 and last traded at $5.09. 19,907 shares traded hands during mid-day trading, an increase of 90% from the average session volume of 10,480 shares. The stock had previously closed at $5.39.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of TransCode Therapeutics in a research report on Tuesday, April 21st. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has an average rating of “Sell”.

TransCode Therapeutics Price Performance

The company has a market cap of $4.84 million, a PE ratio of -0.10 and a beta of 1.39. The company’s 50 day simple moving average is $8.00 and its two-hundred day simple moving average is $8.66.

TransCode Therapeutics (NASDAQ:RNAZ) last released its quarterly earnings results on Friday, May 15th. The company reported ($21.28) earnings per share (EPS) for the quarter.

About TransCode Therapeutics

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B.